![rapt therapeutics stock news rapt therapeutics stock news](https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2021/insider_trade_image_578.jpeg)
- #RAPT THERAPEUTICS STOCK NEWS DRIVERS#
- #RAPT THERAPEUTICS STOCK NEWS FULL#
- #RAPT THERAPEUTICS STOCK NEWS REGISTRATION#
Any other use, including for any commercial purposes, is strictly prohibited without our express prior written consent. You may use and the contents contained in solely for your own individual non-commercial and informational purposes only. Liable for your own investment decisions and agree to the Users should not base their investment decision upon. The Company is also pursuing a range of targets that are in the discovery stage of is a research service that provides financial data and technical analysis of publicly traded stocks.Īll users should speak with their financial advisor before buying or selling any securities.
![rapt therapeutics stock news rapt therapeutics stock news](https://www.bioworld.com/ext/resources/Stock-images/Money/Stock-chart-upward-arrow.png)
RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.
#RAPT THERAPEUTICS STOCK NEWS DRIVERS#
Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. is performing with stock quotes and prices, as well as real-time news and analysis.
#RAPT THERAPEUTICS STOCK NEWS REGISTRATION#
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Find the latest RAPT Therapeutics, Inc., RAPT stock market data. 6105 or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by email at or by telephone at (800) 747-3924. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at or by telephone at (866) 803-9204 SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by email at or by telephone at (800) 808-7525, ext.
![rapt therapeutics stock news rapt therapeutics stock news](http://www.stoxline.com/stock_chart/PRQR.gif)
The final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at Alternatively, electronic copies of the final prospectus supplement and the accompanying prospectus may also be obtained from: J.P. The offering was made only by means of a prospectus supplement and accompanying prospectus. The offering was made pursuant to a shelf registration statement, including a base prospectus, filed by RAPT with the Securities and Exchange Commission (SEC), which was declared effective by the SEC on November 16, 2020. and Roth Capital Partners acted as co-lead managers for the offering. Cantor acted as book-running manager for the offering. The stock has a consensus analyst rating of 'Buy.' A 'buy' rating indicates that analysts believe RAPT will outperform the market and that investors should add to their positions of RAPT Therapeutics. Morgan, SVB Leerink and Piper Sandler acted as joint lead book-running managers for the offering. RAPT Therapeutics currently has 6 buy ratings from Wall Street analysts. The aggregate gross proceeds to RAPT from the offering were approximately $143.7 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares of common stock were offered by RAPT.
#RAPT THERAPEUTICS STOCK NEWS FULL#
SOUTH SAN FRANCISCO, Calif., J(GLOBE NEWSWIRE) - RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the closing of its previously announced underwritten public offering of 4,356,060 shares of its common stock at a price to the public of $33.00 per share, which includes 568,181 shares issued and sold upon full exercise of the underwriters’ option to purchase additional shares of common stock.